Fresenius Medical Care (NYSE:FMS) Shares Gap Down to $21.42

Fresenius Medical Care AG (NYSE:FMS)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $21.42, but opened at $19.87. Fresenius Medical Care shares last traded at $19.94, with a volume of 69,024 shares.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Saturday, May 4th. They set a “strong-buy” rating on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Trading Up 1.0 %

The company has a current ratio of 1.42, a quick ratio of 1.07 and a debt-to-equity ratio of 0.47. The firm’s 50-day moving average is $19.69 and its 200-day moving average is $19.66. The firm has a market cap of $12.25 billion, a price-to-earnings ratio of 22.70, a P/E/G ratio of 1.16 and a beta of 0.95.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.11. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. The firm had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.32 billion. As a group, sell-side analysts anticipate that Fresenius Medical Care AG will post 1.49 EPS for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently announced an annual dividend, which will be paid on Monday, June 3rd. Stockholders of record on Monday, May 20th will be issued a $0.437 dividend. The ex-dividend date is Friday, May 17th. This represents a dividend yield of 2.35%. Fresenius Medical Care’s dividend payout ratio is presently 46.74%.

Institutional Investors Weigh In On Fresenius Medical Care

Several institutional investors have recently bought and sold shares of the stock. Bruce G. Allen Investments LLC purchased a new position in Fresenius Medical Care during the 4th quarter worth $31,000. Hartford Financial Management Inc. boosted its holdings in Fresenius Medical Care by 98.8% during the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock worth $35,000 after purchasing an additional 839 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Fresenius Medical Care by 349.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock worth $48,000 after purchasing an additional 1,799 shares in the last quarter. GAMMA Investing LLC purchased a new stake in Fresenius Medical Care in the 4th quarter valued at about $67,000. Finally, Assetmark Inc. lifted its position in shares of Fresenius Medical Care by 169.9% during the 4th quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after buying an additional 2,630 shares in the last quarter. Institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.